Didn't like the old AbbVie? Perhaps you should consider New AbbVie. The pharma giant laid out its case for a $46 billion takeover of Shire today, insisting that their complementary pipelines and product base covering a full range of categories, global sales operations and a quick tax inversion--moving its tax base to the U.K. while retaining its headquarters in Chicago--made the numbers for a post-merger New AbbVie look great.
Endo, in a world of financial hurt, has been turning to M&A lately to ease the pain. Its latest move: a deal for New Jersey generics maker DAVA Pharmaceuticals worth up to $600 million.
Abbott Laboratories has said it plans to focus its branded generics business on a select group of rapidly expanding emerging markets. It appears Russia is one of them. The Illinois-based drugmaker will shell out up to $495 million to buy the fast-growing Russian generics maker VeroPharm from local billionaire Roman Avdeev.
Allergan's board has already rejected Valeant's $53 billion buyout bid, prompting the wannabe-acquirer to take the proposal directly to shareholders. Unsurprisingly enough, Allergan's board doesn't like that too much, either. And if you ask Valeant, it's twisting the facts to get shareholders on its side.
After dismissing three escalating takeover bids from AbbVie as too cheap, Shire is promising to double its annual sales by 2020, touting its pipeline as a blockbuster farm best tended without outside meddling.
Shire has maintained that it's better off alone, rejecting three recent merger bids from AbbVie worth as much as $46.5 billion. Now, it's laying out its case. The Irish drugmaker outlined a plan to double sales by 2020--but that may not be enough to keep predators at bay.
Welsh CRO Simbec Research is expanding beyond its focus on early-phase studies, buying up Orion Clinical Services in a move the company says will make it a full-service organization.
Just three months after wrapping its latest merger, BioClinica has made another acquisition, snapping up Blueprint Clinical to expand its capabilities in the growing field of risk-based management.
Spun off from Abbott Laboratories early last year, AbbVie right now is somewhat of a one-trick pony, with lead drug Humira--the best-selling med in the world--raking in 57% of its 2013 sales. Though it has some hot prospects in its pipeline, it could use some other revenue sources, and it apparently thinks Shire might be able to help it out in that department--and bring along some tax advantages, too.
Medtronic is looking forward to reaping the benefits of its new Irish domicile after its $42.9 purchase of Covidien, but the tax inversion process will not be all fun and games, according to tax experts.